The promising results of coumarin-based benzamides as potent HDAC inhibitors with anticancer activity encouraged the design of coumarins containing a hydroxamate moiety as HDAC inhibitors based on the structure of an FDA-approved deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma—vorinostat, also known as suberoylanilide hydroxamic acid (SAHA, Figure 29) [132]. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.